Modelling genetic and clinical heterogeneity in epithelial ovarian cancers

被引:30
作者
Lawrenson, Kate
Sproul, Duncan [2 ]
Grun, Barbara [1 ]
Notaridou, Maria [1 ]
Benjamin, Elizabeth [3 ]
Jacobs, Ian J. [1 ]
Dafou, Dimitra [1 ]
Sims, Andrew H. [2 ]
Gayther, Simon A. [1 ]
机构
[1] UCL, Gynaecol Canc Res Labs, UCL EGA Inst Womens Hlth, London WC1E 6DD, England
[2] Western Gen Hosp, Appl Bioinformat Canc Grp, Edinburgh Breakthrough Res Ctr, Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland
[3] UCL, Dept Histopathol, Inst Canc, London WC1E 6JJ, England
基金
英国医学研究理事会;
关键词
EXPRESSION PROFILES; BORDERLINE TUMORS; GROWTH-FACTOR; LOW-GRADE; C-MYC; MUTATIONS; CARCINOMA; CELLS; KRAS; TRANSFORMATION;
D O I
10.1093/carcin/bgr140
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The biology underlying early-stage epithelial ovarian cancer (EOC) development is poorly understood. Identifying biomarkers associated with early-stage disease could have a significant impact on reducing mortality. Here, we describe establishment of a three-dimensional (3D) in vitro genetic model of EOC initiation and early-stage neoplastic progression. Normal primary ovarian epithelial (POE) cells, immortalized using hTERT (immortalised ovarian epithelial [IOE] cells), were partially transformed by overexpressing the CMYC oncogene (IOECMYC cells). Subsequent expression of mutant alleles of KRAS (KRAS(G12V)) or BRAF (BRAF(V600E)) created double-mutant lines (IOECMYC.KRAS and IOECMYC.BRAF). The transformed phenotype of IOECMYC cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOECMYC cells had undergone morphological and phenotypic changes characteristic of neoplastic progression. When cultured as 3D spheroids, IOE cells underwent growth arrest, reminiscent of nonproliferative, unstimulated POE in vivo. In contrast, IOSECMYC+BRAF/KRAS cells formed highly proliferative, poly-aggregate spheroid structures, showing increased expression of the Wilms tumour 1 tumourigenic marker and MIB1 proliferation marker. Transcriptomic analyses identified different gene expression profiles between the different cell lines and novel candidate genes (e.g. RGS4, CTGF and THBS1) that are somatically altered in EOCs. Gene expression signatures were compared with signatures from primary EOCs; tumours with IOECMYC 'like' signatures were more likely to be high grade (P = 0.018); tumours with BRAF signatures were associated with improved relapse-free survival (P = 0.003). In conclusion, we have established in vitro 3D models of early-stage EOCs, which reflect genetic and phenotypic heterogeneity of the disease. Molecular genetic characteristics of these models correlated with molecular and clinical features of primary EOCs.
引用
收藏
页码:1540 / 1549
页数:10
相关论文
共 50 条
  • [21] The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review
    Lau, Chien-Hui
    Seow, Kok-Min
    Chen, Kuo-Hu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
  • [22] Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics
    Zhang, Meiying
    Zhuang, Guanglei
    Sun, Xiangjun
    Shen, Yanying
    Zhao, Aimin
    Di, Wen
    JOURNAL OF OVARIAN RESEARCH, 2015, 8
  • [23] Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity
    Bodelon, Clara
    Killian, J. Keith
    Sampson, Joshua N.
    Anderson, William F.
    Matsuno, Rayna
    Brinton, Louise A.
    Lissowska, Jolanta
    Anglesio, Michael S.
    Bowtell, David D. L.
    Doherty, Jennifer A.
    Ramus, Susan J.
    Talhouk, Aline
    Sherman, Mark E.
    Wentzensen, Nicolas
    CLINICAL CANCER RESEARCH, 2019, 25 (19) : 5937 - 5946
  • [24] A Translational Model to Improve Early Detection of Epithelial Ovarian Cancers
    Gockley, Allison
    Pagacz, Konrad
    Fiascone, Stephen
    Stawiski, Konrad
    Holub, Nicole
    Hasselblatt, Kathleen
    Cramer, Daniel W.
    Fendler, Wojciech
    Chowdhury, Dipanjan
    Elias, Kevin M.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Treatment planning of epithelial ovarian cancers using helical tomotherapy
    Jamema, Swamidas V.
    Mahantshetty, Umesh
    Goel, Vineeta
    Engineer, Reena
    Deshpande, Deepak D.
    Sarin, Rajiv
    Shrivastava, Shyam Kishore
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2009, 10 (04): : 96 - 105
  • [26] Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers
    Han, Jasmine J.
    Yu, Minshu
    Houston, Nicole
    Steinberg, Seth M.
    Kohn, Elise C.
    GYNECOLOGIC ONCOLOGY, 2011, 120 (01) : 5 - 10
  • [27] Is Routine Nodal Dissection in Early Epithelial Ovarian Cancers Required?
    Agarwal, Arjun
    Hemanth, G. N.
    Garg, Cheena
    Ganesh, M. S.
    Keerthi, B. R.
    Prabha, Amritha
    Abhinay, I.
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 18 (03)
  • [28] Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
    Azzalini, Eros
    Stanta, Giorgio
    Canzonieri, Vincenzo
    Bonin, Serena
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (20)
  • [29] Chemoresistance Is Associated with MUC1 and Lewis y Antigen Expression in Ovarian Epithelial Cancers
    Zhang, Danye
    Gao, Jian
    Zhu, Liancheng
    Hu, Zhenhua
    Hou, Rui
    Liu, Shuice
    Tan, Mingzi
    Liu, Juanjuan
    Lin, Bei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (06): : 11024 - 11033
  • [30] Etiology and pathogenesis of epithelial ovarian cancer
    Mok, Samuel C.
    Kwong, Joseph
    Welch, William R.
    Samimi, Goli
    Ozbun, Laurent
    Bonome, Tomas
    Birrer, Michael J.
    Berkowitz, Ross S.
    Wong, Kwong-Kwok
    DISEASE MARKERS, 2007, 23 (5-6) : 367 - 376